| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | PKCB; PRKCB1; PRKCB2; PKC-beta |
| WB Predicted band size | 77 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human PRKCB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PRKCB抗体的3篇示例参考文献(内容为模拟生成，仅供参考)：
1. **标题**：*Protein kinase C β activates fat mass and obesity-associated protein by phosphorylation*
**作者**：Li, Y. et al.
**摘要**：本研究揭示了PRKCB通过磷酸化调控脂肪代谢相关蛋白FTO的分子机制，利用PRKCB特异性抗体进行免疫共沉淀实验，证实其在肥胖相关信号通路中的关键作用。
2. **标题**：*PRKCB modulates synaptic plasticity and memory formation via NMDA receptor regulation*
**作者**：Saito, T. et al.
**摘要**：通过在小鼠模型中使用PRKCB抗体进行脑组织免疫荧光染色，研究发现PRKCB通过调控NMDA受体亚基的突触定位影响记忆形成，为阿尔茨海默病治疗提供新靶点。
3. **标题**：*Targeting PKCβ in chronic lymphocytic leukemia: Antibody-based therapeutic strategies*
**作者**：Montalban, G. et al.
**摘要**：文章评估了PRKCB抗体在慢性淋巴细胞白血病(CLL)中的治疗潜力，通过体外实验证明特异性抑制PRKCB可诱导癌细胞凋亡并增强化疗敏感性。
---
**注意**：以上文献为示例，实际引用请通过PubMed/Google Scholar检索真实论文(关键词：PRKCB antibody, protein kinase C beta, 研究领域如cancer/neuroscience等)。近年研究可能集中在PRKCB与肿瘤耐药性、神经炎症或代谢疾病的关联。
PRKCB (Protein Kinase C Beta) antibodies are essential tools in studying the function and expression of the PRKCB protein, a member of the protein kinase C (PKC) family. PKC enzymes are serine/threonine kinases involved in diverse cellular processes, including proliferation, differentiation, apoptosis, and immune responses. PRKCB, specifically, is a classical PKC isoform activated by calcium ions (Ca²⁺) and diacylglycerol (DAG), playing critical roles in signal transduction pathways such as NF-κB and MAPK. It is expressed in various tissues, with notable activity in the brain, immune cells, and vascular endothelium.
Research using PRKCB antibodies has linked this kinase to pathological conditions, including cancer (e.g., promoting tumor angiogenesis and metastasis), diabetic complications (e.g., retinopathy and nephropathy), and neurological disorders (e.g., Alzheimer’s disease). Antibodies targeting PRKCB are employed in techniques like Western blotting, immunohistochemistry, and flow cytometry to assess protein levels, cellular localization, and post-translational modifications. Some studies also explore PRKCB inhibition as a therapeutic strategy, underscoring the antibody's utility in drug development. Notably, PRKCB exists as two splice variants (βI and βII), and antibodies may differentiate between isoforms, aiding in isoform-specific functional studies. Careful validation is required to ensure specificity, given structural similarities among PKC family members.
×
